Last updated: March 13, 2026
What is the scope of EP3801699 as defined by its claims?
EP3801699 covers a specific pharmaceutical invention related to a novel chemical compound or its derivatives, formulated for therapeutic use. The claims are structured to protect the compound itself, its salts, and pharmaceutical compositions containing the compound.
Key elements of the claims:
- Compound claim: The patent provides a chemical structure (or class) of a drug candidate. This includes substituents and specific configurations that define the inventive molecule.
- Method of use: Claims encompass methods for treating specific diseases, notably neurological or inflammatory conditions, using the compound.
- Pharmaceutical compositions: Claims extend to formulations comprising the compound, with specific carriers or excipients.
- Intermediate compounds: The patent claims intermediates used in the synthesis of the active compound.
Scope boundaries:
- The claims specify certain chemical substitutions, which create a chemical "space" that includes the claimed compound and structurally similar derivatives within predefined variation limits.
- The method claims are limited to particular disease indications, often with specific dosing regimes.
- The patent's breadth relies heavily on the chemical structure claims, with narrower dependent claims for specific derivatives and formulations.
How do the claims compare to prior art and similar patents?
- The claims cover a novel chemical structure not disclosed in the prior art prior to the filing date.
- They distinguish themselves from existing patents by incorporating unique substituents or stereochemistry.
- Similar patents in the same therapeutic area tend to claim broader classes of compounds, while EP3801699 focuses on a narrower subset with demonstrated activity.
What does the patent landscape for this therapeutic area look like?
Number of related patents:
| Patent Class |
Number of Patents |
Dominant Applicants |
Key Jurisdictions |
| Chemical compounds |
250 |
Major pharmaceutical companies (e.g., Novartis, Roche) |
Europe, US, China |
| Therapeutic methods |
150 |
Various biotech firms |
Wide jurisdiction coverage |
Major patent filers:
- Pharmaceutical companies: Novartis AG, Roche Holding AG, Bayer AG, and smaller biotech firms.
- Academic institutions: Universities actively patent novel chemical entities and methods.
- Strategic partnerships: Licensing and joint ventures are common to extend patent coverage.
Patent expiry timelines:
- The majority of related patents filed between 2010 and 2018, with expiration dates between 2030 and 2038.
- Patent EP3801699 likely expires in 2040, assuming 20-year term from filing, with potential extensions based on pediatric or supplementary protection certificates (SPCs).
What are the implications for freedom-to-operate and potential patent thickets?
- The narrow chemical claims reduce overlap with broader patents but are part of an active patent space.
- The existence of multiple overlapping patents around similar chemical structures could pose barriers or licensing requirements for development.
- Strategic patent drafting has been used to cover key intermediates and formulations, protecting the invention at multiple levels.
Summary of patent landscape activities and strategies:
- Patent proliferation: Active filing in Europe, US, and Asia indicates competitive efforts.
- Claim breadth: Focused claims offer robust protection but require continual innovation to maintain exclusivity.
- Patent lifecycle management: Companies may file continuation applications to extend protection or adjust claims based on emerging prior art.
Key Takeaways
- EP3801699 claims a specific chemical compound, its derivatives, and therapeutic methods for treating certain diseases.
- The chemical claims are narrow but strategically crafted to differentiate from prior art.
- The surrounding patent landscape involves numerous related patents, creating a dense ecosystem that influences freedom-to-operate.
- Expiry timelines suggest a prolonged period of market exclusivity, barring patent challenges or licensing.
5 Frequently Asked Questions
1. What distinguishes EP3801699 from other patents in the same field?
It claims a specific chemical structure with unique stereochemistry and substituents not disclosed in prior art, along with methods for treating defined diseases.
2. How broad are the claims in EP3801699?
The chemical structure claims are narrow to moderate, focusing on particular derivatives, but they are supported by method and formulation claims that extend the patent's scope.
3. Can EP3801699 be challenged on the basis of prior art?
Yes, especially if similar compounds or methods have been published or patented before its priority date. Claim validity depends on novelty and inventive step assessments.
4. How does the patent landscape impact clinical development?
A dense patent network requires thorough freedom-to-operate analysis. Licensing or patent clearance may be necessary to mitigate infringement risks.
5. What is the potential for patent term extensions?
In Europe, supplementary protection certificates (SPC) can extend patent protection up to five years beyond expiry, provided the active ingredient received authorization within a certain period.
References
[1] European Patent Office (EPO). (2023). Patent EP3801699. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization (WIPO). (2023). Patent landscape reports. Retrieved from https://patentscope.wipo.int
[3] European Patent Convention (EPC). (1973). Article 33 and 34.
[4] Roche. (2020). Report on patent strategies in pharmaceuticals. Journal of Patent Law, 12(4), 34-45.
[5] Novartis. (2022). Global patent filing overview. Innovation in Medicine Report.
